Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
Revisiting Beam Therapeutics Among Collaborative Catalysts
10:06am, Sunday, 10'th Jul 2022
The recent 4-year partnership between Pfizer and Beam Therapeutics involves $300 million upfront to speed validation of the technology and an additional $1.05 billion in milestone payments. A recent a
Top Health Care Stocks To Buy Right Now? 4 To Watch
02:23pm, Saturday, 09'th Jul 2022
Check these health care stocks out for your watchlist right now
The 3 Leaders of the Gene Editing Revolution
04:12pm, Friday, 08'th Jul 2022
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. The post The 3 Leaders of the Gene Editing Revolution appeared f
7 Moonshot Investments Upending a $10 Trillion Industry
03:53pm, Friday, 08'th Jul 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on
Have $1,000 to Invest? 2 Stocks to Buy Right Now That Could Help Make You a Fortune
10:20am, Tuesday, 05'th Jul 2022
These two stocks could generate life-changing gains for patient shareholders.
A Comprehensive Guide to Genomic ETFs
05:43pm, Tuesday, 28'th Jun 2022
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new
Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?
10:06am, Monday, 20'th Jun 2022
Beam Therapeutics Inc. (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri
BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success
02:37pm, Friday, 17'th Jun 2022
BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ: BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-gener
EV Industry Reward-Risk Map
04:55pm, Thursday, 09'th Jun 2022
Stocks tied broadly to the electric vehicle charging industry, as listed today by Seeking Alpha, are shown by their Market-Maker-valued price range limits on 6/8/22 close prices. No comment necessary.
5 Health Care Stocks Cathie Wood Favors
04:07pm, Thursday, 09'th Jun 2022
Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.
3 Cathie Wood Stocks That Could Deliver Monster Returns
09:00am, Saturday, 04'th Jun 2022
Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results
10:30am, Monday, 09'th May 2022 GlobeNewswire Inc.
BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates
09:54am, Monday, 09'th May 2022
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 8.18% and 89.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Lags Revenue Estimates
11:45am, Thursday, 05'th May 2022 Zacks Investment Research
Aeglea (AGLE) delivered earnings and revenue surprises of -5.71% and 6.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
